EpiVax, Inc. engages in the development and implementation of computational immunology analytical tools for epitope discovery, de-immunization, and vaccine design applications. The company utilizes its tools for reengineering therapeutic proteins and designing new vaccines to support its clients' research and development activities, as well as to develop its own pipeline of therapeutic proteins and vaccine candidates. It engages in providing epitope discovery and de-immunization services to researchers and developers in industry and academia; establishing collaborations with pharmaceutical, vaccine, and biotechnology companies focused on biological targets; and conducting internal discovery and design programs aimed at selected biological targets. The company's products include vaccines for the treatment of HIV, TB, tularemia, smallpox, H.pylori, influenza, and HPV; de-immunization products; and immune modulation for use with insulin. Its services include vaccine design and redesign; de-immunization; preclinical screening for immunogenicity; de-immunization of functional therapeutics.
